Secular Trends in Development of End‐Stage Renal Disease Following Liver Transplantation
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70141 ↗At a glance
Journal article in Clinical Transplantation, 2025. Written by Jessica M Ruck and 11 co-authors. Institution: Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Major MEDLINE topics: Liver Transplantation, Kidney Failure, Chronic, Postoperative Complications, Graft Rejection. 18 references. Funded by: National Institutes of Aging, NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (original language)
Background
Renal dysfunction is common among liver transplant candidates and can resolve, persist, or develop de novo following liver transplantation (LT). In light of the 2017 policy changes to simultaneous liver‐kidney transplant and the post‐LT kidney transplant safety net eligibility, we evaluated risk factors for and change in the incidence of post‐LT renal dysfunction.
Methods
Using SRTR data for adult deceased‐donor liver‐only transplant recipients 2010–2022, we evaluated secular trends in and risk factors for the development of post‐LT ESRD at 1 year and overall using multivariable logistic and Cox regression. We compared observed versus expected incidence of ESRD at 1‐year post‐LT using weighting by odds.
Results
Among 77 565 LT recipients, 6032 (7.8%) developed ESRD during the study period, of whom 2354 (39.0%) developed ESRD within the first year after LT. In a multivariable model, diabetes (aOR 1.63, 95% CI 1.48–1.79, p < 0.001), pre‐LT eGFR (aOR 0.97 per unit, 95% CI 0.97–0.97, p < 0.001), and MELD category remained independently associated with ESRD within 1‐year post‐LT. Odds of ESRD by 1 year post‐LT were 47% higher than expected post‐2017 after accounting for changes in donor and recipient characteristics.
Conclusions
The rising 1‐year post‐LT ESRD risk highlights the need to reassess safety net eligibility beyond 1 year and prioritize counseling on risk minimization, including post‐transplant diabetes management and potential adjustments to immunosuppression protocols to improve outcomes.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Surgery, New York University Grossman School of Medicine and Langone Health, New York, New York, USA.
- Department of Population Health, New York University Grossman School of Medicine and Langone Health, New York, New York, USA.
- Scientific Registry of Transplant Recipients, Minneapolis, Minnesota, USA.
ORCID profiles: Maria A Parra, Goutham Nair
Funding
- National Institutes of Aging
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Cite
APA
Ruck, J. M., Parra, M. A., Zeiser, L. B., Nair, G., Kant, S., Philosophe, B., Ottmann, S. E., Cameron, A. M., Wesson, R. N., Massie, A. B., Segev, D. L., & King, E. A. (2025). Secular Trends in Development of End‐Stage Renal Disease Following Liver Transplantation. Clinical Transplantation. https://doi.org/10.1111/ctr.70141
Vancouver
Ruck JM, Parra MA, Zeiser LB, Nair G, Kant S, Philosophe B, et al. Secular Trends in Development of End‐Stage Renal Disease Following Liver Transplantation. Clinical Transplantation. 2025. doi:10.1111/ctr.70141
BibTeX
@article{Ruck2025,
author = {Ruck, Jessica M and Parra, Maria A and Zeiser, Laura B and Nair, Goutham and Kant, Sam and Philosophe, Benjamin and Ottmann, Shane E and Cameron, Andrew M and Wesson, Russell N and Massie, Allan B and Segev, Dorry L and King, Elizabeth A},
title = {Secular Trends in Development of End‐Stage Renal Disease Following Liver Transplantation},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70141}
}
EUVIMED